IP Library › Granted Patent US 12,241,892
Granted Patent B2
US 12,241,892 · App. 16/626,584 · Granted Mar 4, 2025

In situ serial dilution method

Inventor: Emmanuel Guignet (Cressier FR, CH)
Assignee: BIO-RAD EUROPE GMBH
G01N33/54306
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,241,892
App. No.
16/626,584
Granted
Mar 4, 2025
Kind
B2
Abstract

Provided herein are methods of determining a concentration of an analyte in a sample using in situ serial dilution.

Claims (29)

1. A method of determining a concentration of an analyte in a sample by in situ serial dilution, the method comprising:

providing an immunodiagnostic test card, the test card comprising a substantially flat support that supports a plurality of vertically disposed microtubes, each microtube having an incubation chamber for receiving the sample and a reaction chamber comprising a separation matrix;

adding a diluent to at least one of the incubation chambers;

serially diluting the sample directly into each of the incubation chambers having diluent therein;

adding a reagent to each of the incubation chambers having diluent and/or sample therein, wherein the reagent is capable of complexing with the analyte to form a reagent-analyte complex;

exposing the mixture of sample and reagent to sedimentation by gravitation and/or centrifugation; and

determining the concentration of the analyte by determining a highest dilution of the sample at which a reagent-analyte complex is detected on or within the separation matrix.

2. The method of claim 1 , wherein the determining the concentration of the analyte step comprises determining a titer of an antibody and the titer is the highest dilution of the sample for which a reagent-antibody complex is observed corresponding to a reaction strength of “+”.

3. The method of claim 2 , further comprising determining an antibody endpoint and the antibody endpoint is the highest dilution of the sample having visible reagent-antibody complexes.

4. The method of claim 2 , further comprises determining an antibody titer score and the antibody titer score is the sum of the score values assigned to each reaction.

5. The method of claim 2 , wherein the antibody is directed against a red blood cell antigen.

6. The method of claim 1 , wherein the determining the concentration of the analyte step comprises determining the concentration of an antigen.

7. The method of claim 1 , wherein the separation matrix is a polyelectrolyte gel.

8. The method of claim 7 , wherein the polyelectrolyte gel is dextran acrylamide.

9. The method of claim 1 , wherein the reaction chamber further comprises a reticulation agent.

10. The method of claim 9 , wherein the reticulation agent is a secondary antibody.

11. The method of claim 10 , wherein the secondary antibody is anti-human globulin or anti-human IgA antibody.

12. The method of claim 1 , wherein the serially diluting the sample step comprises serially diluting the sample directly into each of the incubation chambers in the same test card or between test cards.

13. The method of claim 1 , wherein the reagent comprises a red blood cell or a coated particle having an antigen or antibody thereon.

14. The method of claim 1 , wherein each microtube further comprises an air gap between the incubation chamber and the reaction chamber.

15. The method of claim 1 , wherein each microtube further comprises a low density immiscible compound between the incubation chamber and the reaction chamber.

16. The method of claim 1 , further comprising mixing the reagent and the sample after the step of adding the reagent to each of the incubation chambers having diluent and/or sample therein.

17. The method of claim 1 , further comprising incubating the test card after the step of adding the reagent to each of the incubation chambers having diluent and/or sample therein.

18. The method of claim 1 , wherein the serially diluting the sample step comprises:

a) at least a two-fold serial dilution of the sample into each of the incubation chambers having diluent therein;

b) less than a two-fold serial dilution of the sample into each of the incubation chambers having diluent therein; or

c) a two-fold serial dilution of the sample into each of the incubation chambers having diluent therein.

19. The method of claim 1 , wherein the sample is selected from the group consisting of serum, plasma, and a calibrator.

20. The method of claim 1 , wherein the analyte is an antibody or an antigen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: GUIGNET, EMMANUEL
To: DIAMED GMBH
Reel/Frame 052003/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: DIAMED GMBH
To: BIO-RAD EUROPE GMBH
Reel/Frame 052039/0684 →
Continuity (2)
Provisional Application 62524832 · Jun 26, 2017
Related Publication 20200116710A1 · Apr 16, 2020
References Cited (30)
US 4305721A · Bernstein · 1981 [cited by applicant]
US 5460940A · Yves et al. · 1995 [cited by applicant]
US 5650068A · Chachowski et al. · 1997 [cited by applicant]
US 6114179A · Lapierre et al. · 2000 [cited by applicant]
US 8187538B2 · Jakubowicz et al. · 2012 [cited by applicant]
US 8496878B2 · Jakubowicz et al. · 2013 [cited by applicant]
US 10509028B2 · Agusti et al. · 2019 [cited by applicant]
US 20110159477A1 · Nilsson et al. · 2011 [cited by applicant]
US 20120282635A1 · Wardlaw et al. · 2012 [cited by applicant]
US 20140141995A1 · Crisanti et al. · 2014 [cited by applicant]
AU 2001258469B2 · 2001 [cited by applicant]
CN 101021540 · 2007 [cited by applicant]
CN 103547921A · 2014 [cited by applicant]
EP 2515271A1 · 2012 [cited by applicant]
JP 2011512524 · 2011 [cited by applicant]
RU 2526820C1 · 2013 [cited by examiner]
WO WO9950673 · 1999 [cited by applicant]
WO WO03044217A2 · 2003 [cited by applicant]
WO WO2005064347 · 2005 [cited by applicant]
WO WO2009097188 · 2009 [cited by applicant]
WO WO2016184924 · 2016 [cited by applicant]
Written Opinion in International Application No. PCT/IB2018/000768, Oct. 30, 2018, pp. 1-7. [cited by applicant]
Scabet. “Precision of Antibody Titration in Gel versus Tube,” AABB Future Leader Scholarship Awards, Published May 21, 2013; 13 pages. https://www.aabb.org/development/scholarships/Documents/12scabet.pdf. [cited by applicant]
Bromilow, I.. DiaMed-ID Micro Typing System “Good Laboratory Practice Titration procedures,” Copyrighted 1999, downloaded Jun. 2, 2017, 8 pages. [cited by applicant]
American Proficiency Institute—2012 1st Test Event “Educational Commentary—Antibody Titrations,” Copyrighted 2012 by American Society of Clinical Pathology, URL: http://www.api-pt.com/Reference/Commentary/2012Abbank.pdf… [cited by applicant]
Novaretti et al. “Comparison of conventional tube test with diamed gel microcolumn assay for anti-D titration,” Clin. Lab. Haem., 2003, vol. 25, pp. 311-315. [cited by applicant]
Insert—“Blood Grouping Reagent DG Gel 8 ABO/Rh + Kell REF 210383 3034946 Instructions for Use.” (2013) Distributed by Novartis Vaccines and Diagnostics, Inc, https://www.fda.gov/media/86207/download, downloaded Apr. 6, … [cited by applicant]
Powell, V., “Blood Group Antigens and Antibodies” NYU Langone Medical Center, PowerPoint slides, Apr. 18, 2017, 69 pages. [cited by applicant]
“MLAB 2461 Clinical II Immunohematology Activity 11 MTS Gel Testing” Austin Community College course: MLAB 2461 Clinical—Clinical/Medical Laboratory Technician II. Web Author: Terry Kotrla, Original publication date: Ja… [cited by applicant]
Endoh, T. et al. “Prewarm Technique Reduces the Detection Efficiency For Rh System Antibodies” [cited by applicant]